Figure 6.

(A) Proptosis responder analysis (percent of patients with ≥2 mm reduction in proptosis from baseline in study eye). (B) Change from baseline in proptosis (least squares mean ± standard error). (C) Percent of patients with clinical activity score (CAS) of 0 or 1 in study eye. (D) Overall responder rate (percent of patients with ≥2-point reduction in CAS and ≥2 mm reduction in proptosis from baseline in study eye). (E) Diplopia response (percent of patients with improvement of at least 1 grade from baseline). (F) Change from baseline in transformed GO-QOL score (least squares mean ± standard error). From N. Engl. J. Med, Douglas R.S, Kahaly G.J., Patel A., Sile E.H.Z., Thompson R. et al. Teprotumumab for the treatment of active thyroid eye disease. 382; 341-352. Copyright ^© (2020) Massachusetts Medical Society. Reprinted with permission.